J&J, Amgen, Regeneron Drugs Likely to Face Medicare Negotiation (1)

Pricey medicines from companies such as Johnson & Johnson and Merck are likely to face government negotiations in coming years, according to a Bloomberg Government analysis of Medicare data.

Sweeping legislation (H.R. 5376) to empower the government to demand lower prices on some of the costliest drugs to Medicare could reach President Joe Biden’s desk by this weekend. Drugs that have been on the market for years and reap billions of dollars in sales from Medicare alone are poised to be on deck.

“These are blockbuster, high revenue products that have made a lot of money for their ...